China Shineway Pharmaceutical Group Limited will convene its Annual General Meeting (AGM) at 11:00 a.m. on Thursday, 28 May 2026, at Suite 3109, 31/F, Central Plaza, Wanchai, Hong Kong.

Key resolutions to be tabled:

1. Financial Statements: Shareholders will vote on adoption of the audited consolidated financial statements, directors’ report and independent auditor’s report for the year ended 31 December 2025.

2. Board Composition and Remuneration: • Re-election of Executive Directors Ms. Xin Yunxia and Mr. Li Huimin, and Independent Non-executive Director Mr. Yew Yat On. • Authorisation for the board to determine directors’ remuneration.

3. Auditor: Re-appointment of Deloitte Touche Tohmatsu, with authority for the board to set audit fees.

4. General Share Issuance Mandate: The board seeks authority to allot, issue or deal in additional shares— including treasury share transfers—up to 20% of the company’s issued share capital (excluding treasury shares) as at the date of the resolution. The mandate will run until the next AGM, expiry of the statutory period for holding the next AGM, or its earlier revocation by shareholders. Exemptions include rights issues, share option or similar schemes, conversions of existing convertible securities, and scrip dividends.

Shareholders’ logistics: The register of members will close from Tuesday, 19 May 2026 to Thursday, 28 May 2026 (both days inclusive). Transfers must be lodged with Computershare Hong Kong Investor Services by 4:30 p.m. on Monday, 18 May 2026 to qualify for AGM attendance and voting. Proxy forms and related authorities must be submitted at the company’s Hong Kong office at least 48 hours before the meeting.

Weather contingency: If a No. 8 (or higher) typhoon signal or black rainstorm warning is in force at 8:00 a.m. on the meeting day, the AGM will be postponed.